A5004079103- Psoriasis: Treatment and Pathogenesis
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hidradenitis Suppurativa and Treatments
- Autoimmune and Inflammatory Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Dupuytren's Contracture and Treatments
- Colorectal Cancer Treatments and Studies
- Patient Satisfaction in Healthcare
- Oral Health Pathology and Treatment
- Autoimmune and Inflammatory Disorders Research
- Pregnancy and Medication Impact
- Mast cells and histamine
- Hair Growth and Disorders
- Complementary and Alternative Medicine Studies
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- melanin and skin pigmentation
- Dermatological and Skeletal Disorders
- Asthma and respiratory diseases
- Spondyloarthritis Studies and Treatments
- Skin Diseases and Diabetes
Polyclinique de Franche Comté
2022-2025
Hôpital Robert-Debré
2010-2021
L’Institut du Cancer Courlancy Reims
2017-2021
Université de Reims Champagne-Ardenne
2009-2019
Centre Hospitalier Universitaire de Reims
2009-2019
Agroécologie
2016
Service de la Santé Publique
2014
Hôpital Maison Blanche
2010
Objective: To investigate the diagnostic value of commercially available BP230 and BP180-NC16a enzyme-linked immunosorbent assays (ELISAs) in routine practice patients with bullous pemphigoid (BP).
<h3>Objective</h3> To identify prognostic factors for relapse in the first year after cessation of therapy bullous pemphigoid (BP). <h3>Design</h3> Prospective, multicenter, cohort study (January 1, 2000, through December 31, 2006). <h3>Setting</h3> Fifteen French dermatology departments. <h3>Patients</h3> Patients with BP remission under low doses topical or systemic corticosteroids. <h3>Interventions</h3> Cessation corticosteroid treatment (day 0) followed by a systematic clinical and...
Abstract Background The development of vitiligo during treatment with biological agents is an unusual event and only a few isolated cases have been reported. Objectives To describe the clinical characteristics evolution patients developing new‐onset following initiation agent for chronic inflammatory disease; also to report course pre‐existing under therapy. Methods This nationwide multicentre, retrospective study, carried out between July 2013 January 2015, describes large series 18...
Abstract Background Age of the patients and age onset psoriasis may have an impact on disease. There is little information about in elderly patients. Objective We evaluated epidemiological, clinical aspects, comorbidities treatments (>70 years) patients, with very late (onset ≥ 70 years). Methods This observational multicentre non‐interventional study adults was conducted 29 departments dermatology France. A total 2210 were included. Results 212 (9.5%) elderly. group had a higher...
Introduction Psoriasis is a chronic inflammatory skin disease that negatively impacts the quality of life patients and their families. However, most commonly used decision-making tools in psoriasis, Area Severity Index (PASI), Physician Global Assessment (PGA) Dermatology Life Quality (DLQI), do not fully capture impact psoriasis on patients’ lives. In contrast, well-established 5-item WHO Well-being (WHO-5) assesses subjective psychological well-being patients. Moreover, while drug...
Journal Article Childhood‐onset psoriasis: association with future cardiovascular and metabolic comorbidities Get access E. Mahé, Mahé Department of Dermatology Hôpital Victor Dupouy Argenteuil France Correspondence Emmanuel E‐mail: emmanuel.mahe@ch-argenteuil.fr Search for other works by this author on: Oxford Academic Google Scholar F. Maccari, Maccari d'Instruction des Armées Bégin Saint‐Mandé A. Beauchet, Beauchet Public Health Centre Hospitalier Universitaire Ambroise Paré University...
Three biotherapies - etanercept, adalimumab and ustekinumab are licensed in childhood psoriasis. The few data available on their efficacy tolerance mainly derived from industry trials. However, biological drug survival impacts long-term performance real-life settings. objective of this study was to evaluate the rates therapies children with psoriasis conditions. Secondary objectives were factors associated choice therapy report severe adverse events. This an observational retrospective...
<b><i>Background:</i></b> In severe alopecia areata (AA), spontaneous recovery is unlikely, and treatment not standardized. <b><i>Ob</i></b><b><i>jective:</i></b> To evaluate the efficacy safety of methotrexate (MTX) used alone or combined with low- to moderate-dose oral corticosteroids (OC) for treating AA (totalis, universalis multifocal). <b><i>Methods:</i></b> Retrospective monocentric study...
<b><i>Background:</i></b> Recently, a consensus Bullous Pemphigoid Disease Area Index (BPDAI) was proposed to measure therapeutic outcomes in bullous pemphigoid (BP). <b><i>Objective:</i></b> To compare BPDAI with other clinical parameters of disease activity at baseline and describe the variations during initial phase treatment. <b><i>Methods:</i></b> Thirty BP patients were included followed for 1 year. assessed on...
Omalizumab is approved as an add‐on therapy for the treatment of chronic spontaneous urticaria (CSU) in patients with inadequate response to H1‐antihistamine treatment. The control test (UCT) a reliable, concise tool developed alternative 7‐day activity score (UAS7) – standard CSU disease assessment. This prospective, open‐label, phase IV study evaluated efficacy and safety omalizumab French adult nonresponsive Patients [n =136; stratified 1 : 2 (with angio‐oedema without angioedema)]...
Psoriasis has major physical, psychological, and social impacts: its management should not be restricted by individual financial considerations in Western countries as these have well-structured health systems social/insurance coverage. We investigated if the socioeconomic characteristics of patients were associated with severity psoriasis access to healthcare. In a cross-sectional study, we included 903 that consulting for first time. showed low educational level was disease multivariate...
Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score ≥ 7 ("BARI dominant") have been characterized as important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim evaluate quality life (QoL) functioning outcomes in adult patients BSA 40% NRS at baseline (BL) who received BARI 4 mg topical corticosteroid (TCS) combination trial BREEZE-AD7. BREEZE-AD7 was...
A significant weight gain has been reported in patients with psoriasis treated anti-tumour necrosis factor-alpha agents. Among these patients, there are contradictory results about risk factors for gain.Assessing increment psoriatic on infliximab (IFX).This study was a 4-month, non-interventional, cross-sectional, multicentre adults performed 19 French dermatological centres. All the who received IFX at least 1 year were prospectively included, retrospective analysis of data. Impact sex,...
Abstract Anti‐tumor necrosis factor ( TNF )‐α agents may induce skin reactions, in particular patients with inflammatory bowel diseases IBD ). The objective of this study was to determine the efficacy ustekinumab these patients. facing therapeutic issues because cutaneous reactions or tolerance issues, consequently treated our department, were included. Retrospective review case records and clinical photographs carried out. Twenty‐six Twenty‐three for Crohn's disease three ulcerative...
Abstract Background There is limited information about active tuberculosis (TB) occurring in psoriasis patients treated with Tumor necrosis factor (TNF) antagonists. Objective To describe the clinical characteristics of TB TNF Methods Nationwide retrospective study having experienced TB. Cases were collected via three methods: search national pharmacosurveillance database, questionnaire to members French research group, college dermatology professors. We demographic data, antagonist used,...